MedTrace Logo

Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

NCT05385250 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-08-15

No results posted yet for this study

Summary

This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. the trial aim to lower the risk of bone damage, while adhering with the constrains to the bowel, bladder and other conventional Organs At Risk, and finally to describe the fraction of pelvic insufficiency fractures in patients treated with optimized radiotherapy.

Conditions

Interventions

OTHER

Bone sparring radiotherapy

Observation of late side effects from the pelvic bones after bone-sparring radiotherapy for anal cancer

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • Zealand University Hospital

    collaborator OTHER

  • Vejle Hospital

    collaborator OTHER

  • Karen-Lise Garm Spindler

    lead OTHER

Principal Investigators

  • Karen-Lise G Spindler, DMSc, PhD · Experimental Clinical Oncology, AUH, And Danish Anal Cancer Group, DACG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2025-01-01
Completion
2026-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385250 on ClinicalTrials.gov